Oncolytics Biotech Inc.
NASDAQOncolytics Biotech heads into its May 8 earnings report with the most compelling signal coming not from the options desk, but from the boardroom. Ten insiders bought shares on or around February 12 — including the CEO, CFO, Chief Medical Officer, Chairman, and multiple independent directors. Every recent insider transaction has been a purchase. Net insider buying over the past 90…
ONCY utilization hits 94.17%, near its 52-week peak of 100%, signaling tight borrow availability for short sellers.
Snapshot as of 7 May 2026
Oncolytics Biotech heads into its May 8 earnings report with the most compelling signal coming not from the options desk, but from the boardroom. Ten insiders bought shares on or around February 12 — including the CEO,…
Why this matters — Three distinct ORTEX data points have aligned on ONCY (Oncolytics Biotech Inc.) within a single session. Borrow utilization near its 52-week peak, a rising cost to borrow, and call-skewed options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ONCY — free to start on ORTEX.
Sign up for free →Open ONCY on ORTEX